Carbios’s Wild Week: A 26% Rally in a Stock Without a Safety Net
Published on 07/26/2026 at 19:02 | Redaktion boerse-global.de
Shares of French biotech Carbios surged 7.02% on Friday to close at €6.86, capping a seven-session rebound of 26.34% that has lifted the stock roughly 36% above its 2025 low of €5.05, hit on June 11. Yet for all the recent fireworks, the year-to-date scoreboard still shows a punishing 39.29% decline — a stark reminder that short-term momentum and long-term reality remain deeply disconnected.
The rally comes at a curious moment. Carbios recently announced it is expanding its PET recycling licensing model into the textile market, following successful production trials at its industrial demonstrator in Clermont-Ferrand. That operational validation is genuine. But it does nothing to resolve the single biggest question hanging over the stock: whether the company can secure financing for its flagship Longlaville industrial project before the window closes.
The Market Maker Has Left the Building
Carbios published a report on its liquidity agreement with Natixis ODDO BHF, the bank that had managed the contract since June 2020 until it was suspended on January 19, 2026. The numbers tell a stark story. In the last half-year before the suspension, the bank sold 512,000 shares worth roughly €4.7 million under the agreement. In the most recent reporting period, that figure collapsed to just 29,096 shares for about €334,000. The market maker has effectively vanished.
Without that buffer, the order book is thinner than it has been in years — and price swings are magnified accordingly. The annualized 30-day volatility of 96.17% explains why a stock like Carbios can gain more than a quarter in a single week. It also explains why those gains could evaporate just as quickly. Short-term traders should keep a close eye on the €6.80 level; whether the stock can defend that mark will likely determine if the rally has legs or fades.
Should investors sell immediately? Or is it worth buying Carbios?
China Expansion Gets the Green Light
Amid the market mechanics, Carbios’s annual general meeting delivered a strategic headline. Shareholders approved all agenda items with over 87% support, and the key decision was the creation of a joint venture with Chinese partner Wankai. The new entity, Kaibio Biotechnology, will build and operate China’s first PET biorecycling plant under a licensing agreement with Carbios.
This China initiative represents a distinct expansion path for Carbios’s licensing model, separate from its European industrial plans. But the timeline has already slipped: the Kaibio plant in Haining is now expected to start up in the first half of 2028, later than originally anticipated. Moreover, Carbios and Wankai have mutually agreed to postpone Wankai’s planned €5 million capital increase, originally scheduled for the first half of 2026, to no later than December 31, 2026 — subject to Chinese regulatory approval.
The shareholder turnout of roughly 27.7% of voting capital is typical for a small-cap biotech listed on Euronext Growth, but the concentrated ownership structure has not shielded management from scrutiny. The activist shareholder group ADISECT has raised unanswered questions about governance, licensing terms, and the protection of what it calls a strategic French technology, demanding more transparency on the joint venture’s legal and financial conditions.
The Financing Question That Won’t Go Away
Carbios wants to restart the Longlaville project as soon as financing is secured, with a target completion date in the third quarter of 2026. Management has described the talks as “constructive but not yet concluded.” The third quarter is already underway, and the coming weeks will determine whether this long-running saga finally reaches a resolution — or suffers yet another delay.
The bull case rests on several pillars. Carbios has secured €42.5 million in public funding for Longlaville. Pre-sales agreements already cover nearly 50% of future production capacity, a figure the company aims to raise to 70%. Regulatory tailwinds are also building: France’s IMPR decree offers a bonus of up to €1,000 per tonne for incorporating recycled plastic from hard-to-recycle waste streams, while the EU’s Single-Use Plastics Directive recognizes chemical recycling and restricts the crediting of imported r-PET from outside the bloc by November 2027.
If Longlaville financing closes as planned and textile licensing deals translate into signed contracts, the current recovery from the 52-week low could extend further. The stock still trades 20.46% below its 200-day moving average of €8.62 — leaving room for a re-rating if the news flow turns decisively positive.
The Pattern of Delay
The bear case is equally well-documented. Longlaville’s commissioning has been pushed back multiple times. The China joint venture, once touted as a faster route to industrialization, is now running behind schedule. Legal disputes linger: two lawsuits are pending against Carbios and its management following the departure of former executive Philippe Pouletty.
Carbios at a turning point? This analysis reveals what investors need to know now.
The pattern is consistent: delay follows delay. With annualized 30-day volatility near 96%, any fresh setback — whether on Longlaville financing, the China timeline, or the legal front — could erase the recent gains as quickly as they appeared.
What Comes Next
Until Carbios delivers a binding financing announcement rather than “constructive progress,” the stock is likely to remain trapped in the pattern that has defined the past twelve months: sharp rallies on operational or commercial milestones, followed by skepticism when financing deadlines come and go.
The key milestones to watch are a formal announcement on Longlaville financing, expected around the third quarter of 2026, and further updates on progress toward the 70% pre-commercialization capacity threshold that Carbios has linked to the plant’s construction decision. If those boxes are checked and new textile licensing deals follow, a test of the 200-day moving average near €8.62 becomes plausible. If the financing slips again — as it has repeatedly for both the French and Chinese projects — the 52-week low of €5.05 will remain a relevant downside marker.
For now, the stock is riding high on thin liquidity and genuine operational progress. Whether that combination is sustainable depends entirely on the answer to the question that has haunted Carbios for quarters: can it get the money, or will the delays become the story that defines the year?
Ad
Carbios Stock: New Analysis - 26 July
Fresh Carbios information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
